Modality
Multispecific
MOA
BCL-2i
Target
CDK2
Pathway
Hedgehog
MyelofibrosisFSGS
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Jul 2031
Phase 2Current
NCT06996070
1,441 pts·FSGS
2018-10→2026-07·Completed
NCT04837115
1,850 pts·Myelofibrosis
2021-03→2031-07·Active
3,291 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-194mo awayPh2 Data· FSGS
2031-07-275.3y awayPh2 Data· Myelofibrosis
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Complet…
P2
Active
Catalysts
Ph2 Data
2026-07-19 · 4mo away
FSGS
Ph2 Data
2031-07-27 · 5.3y away
Myelofibrosis
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06996070 | Phase 2 | FSGS | Completed | 1441 | EASI-75 |
| NCT04837115 | Phase 2 | Myelofibrosis | Active | 1850 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |